Is Taysha Gene Therapies financially healthy?
Not really
Taysha Gene Therapies earns only -2,501.2 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDANet cash
Cash vs. debt$320M vs. $70M
Current ratio14.0×Short-term assets for each $1 of bills due within a year
Interest coverage-2,501.2×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Taysha Gene Therapies
Data as of Nov 13, 2026.